Cibus Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.3M+2.0% YoYTTM through 30 Jun 2026
Net Income -$98.2MTTM through 30 Jun 2026
Free Cash Flow -$46.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -720.9% |
| Net Margin | -2,258.9% |
Returns
-203.1%ROE
-22.2%ROA
Balance Sheet Health
Debt / Equity6.88x
Current Ratio2.38x
Net Debt$213.7M
Cash & Equivalents$20.4M
Quality Metrics
Altman Z-Score-4.40
Piotroski F-Score4 / 9
FCF Margin-1,065.6%
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2025: $3.6M
Diluted EPS-$1.51TTMFY2025: $-2.78
Dividend
No dividend
Capital Allocation
Capex Intensity6.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Trait Licensing and Collaboration | $1.7M | +62.6% | View detailsCommercial revenues are expected to begin ramping up in late 2026 and 2027, with a targeted Latin American launch in 2027 and a refined U.S. launch targeted for 2029. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.